UNSPSC 51453201: Oxamniquine

This classification denotes an antihelminthic agent with the molecular formula C14H21N3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0O977R722D, chemically known as 1,2,3,4-tetrahydro-2-((isopropylamino)methyl)-7-nitro-6-quinolinemethanol but generally known as oxamniquine, which bears US NIH Compound Identifier 4612. European Medicines Agency schedules Oxamniquine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09494MIG.

UNSPSC 51453201 Oxamniquine is a Commodity code for a specific antiparasitic pharmaceutical product, but the recent state and local procurement activity tagged under this code shows little alignment with oxamniquine itself. The two opportunities in the most-recent block reference completely different drugs: the Illinois Department of Public Health awarded a piggyback contract through MMCAP Infuse to Chartwell Rx LLC for Doxycycline Hyclate 100mg tablets and Ciprofloxacin Hydrochloride 500mg tablets (both antibiotics, not antiparasitics), and Seminole County, Florida solicited Naloxone and Safe Drug Deactivation Systems. The Seminole County procurement is particularly unrelated to the code's nominal scope. These mismatches suggest that either the opportunities were incorrectly tagged at the commodity level or the state and local procurement systems are using the code loosely. State and local health agencies and counties appear to be the issuing bodies active in this space, though the actual pharmaceutical products being bought do not correspond to oxamniquine.

Geographic activity centers on Florida and Illinois based on the recent records, though the sample is too small and misaligned to establish reliable patterns. The Illinois contract, completed in August 2026, was a $2,999,999.11 award with a 12-month initial term and two renewal options. The Seminole County opportunity, posted June 30, 2026, sought annual quantities of 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems with quarterly deliveries and an initial two-year term with one-year renewal option. Neither opportunity shows explicit set-aside designations. Given the poor fit between the code definition and what is actually being solicited, firms pursuing work in pharmaceutical supply to state and local health agencies should verify the correct commodity codes before targeting opportunities or building forecast models against this code.